NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020
| Autor: | Deepa Jagadeesh, Joan Guitart, Gaurav Goyal, Ahmad Halwani, Eric D. Jacobsen, Richard T. Hoppe, Jasmine Zain, Mary A. Dwyer, Aaron C. Shaver, Jeffrey A. Barnes, Ryan A. Wilcox, Steven M. Horwitz, Ahmet Dogan, Mark W. Clemens, Basem M. William, Elise A. Olsen, Youn H. Kim, Amitkumar Mehta, Stephen M. Ansell, Bradley M. Haverkos, Andrei R. Shustov, Lubomir Sokol, Barbara Pro, Stefan K. Barta, Carlos A. Torres-Cabala, Neha Mehta-Shah, Satish Shanbhag, Weiyun Z. Ai, Pallawi Torka, Hema Sundar, Matthew A. Lunning, Saurabh Rajguru, Aaron M. Goodman, Kristopher R. Fisher |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Mycosis fungoides business.industry Disease medicine.disease Systemic therapy Dermatology Lymphoma Romidepsin 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Oncology Novel agents 030220 oncology & carcinogenesis Mogamulizumab medicine Brentuximab vedotin business medicine.drug |
| Zdroj: | Journal of the National Comprehensive Cancer Network. 18:522-536 |
| ISSN: | 1540-1413 1540-1405 |
| DOI: | 10.6004/jnccn.2020.0022 |
| Popis: | Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|